L&C Bio Signed $60 Million U.S. Supply Agreement
The medical product supplier aims to begin importing Re2O tissue grafts into the U.S. market starting in 2027.
Updated on Oct. 12, 2026 in Biotech
Live Poll
Do you trust that new medical supply partnerships will increase access to quality healthcare in your area?
L&C Bio has entered an exclusive agreement to supply at least $60 million worth of its Re2O product to a U.S. distribution partner. The arrangement leverages the partner's network of approximately 17,000 medical clients to enter the American market.
Why it matters
This agreement marks a major expansion for L&C Bio into the U.S. biotech sector, facilitated by an established tissue bank licensing network. The deal provides a roadmap for increasing production capacity ahead of the scheduled 2027 market entry.
The deal establishes a minimum purchase volume of 150mg of Re2O, excluding the Fine and V variants. The supply will enter the U.S. under the FDA Section 361 HCT/P regulatory framework, which covers human cells, tissues, and cellular and tissue-based products.
The players
L&C Bio
A biotech company specializing in regenerative medical products and human tissue grafts.
The details
Re2O is a medical tissue graft product designed for use in regenerative procedures. To meet the contract's volume requirements, L&C Bio is upgrading existing manufacturing facilities and constructing a new plant in Dongtan. The company will spend the remainder of 2026 conducting academic outreach and product education to prepare U.S. medical professionals for the rollout.
Timeline
Product education for medical professionals occurs throughout the remainder of 2026.
Supply of the Re2O product to the U.S. market is scheduled to begin in 2027.
The Tech Race
This move places L&C Bio within the competitive landscape of standardized regenerative tissue products in the U.S. market. By securing a massive distribution network now, the company aims to establish a foothold before potentially expanding its portfolio to include the Re2O Fine and V variants.
Medical professionals within the distributor's 17,000-client network will receive educational materials and academic training on Re2O throughout 2026. Clinical availability for these providers is expected to follow the launch of supply operations in 2027.
The takeaway
The $60 million contract signals a significant, long-term scaling effort for L&C Bio's tissue graft production. Interested parties should track the 2027 launch date to see if the company successfully adds the Re2O Fine and V variants to its U.S. distribution efforts.
Further reading
Learn more about the latest developments in medical technology and supply chain expansion in our Biotech section.
Live Poll
Do you trust that new medical supply partnerships will increase access to quality healthcare in your area?
